Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Viking Therapeutics said its obesity program is in Phase III with both VANQUISH-1 and VANQUISH-2 fully enrolled, and it expects top-line data in the second half of 2027. The company also plans to move its oral obesity tablet into two Phase III trials later in 2026 after showing a strong weight-loss trajectory in Phase II. The update is constructive for the pipeline but largely reiterates timing rather than providing new clinical data.

Analysis

VKTX is increasingly a “platform optionality” story rather than a single-readout story: the market should start valuing the company on the probability of owning both injectable and oral obesity exposure, which raises the strategic value of the asset to large-cap pharma that has been watching the GLP-1 market migrate toward convenience and adherence. The oral program is the more important second-order catalyst because it can re-rate the stock before Phase III efficacy data if enrollment, tolerability, and titration look manageable; that creates a window where sentiment can improve months ahead of the true de-risking event.

The key competitive implication is not just share gain versus other mid-cap obesity names, but pressure on established incretin leaders if an oral option proves meaningfully differentiated on weight-loss slope and tolerability. Even modest efficacy with better convenience can matter because the obesity market is becoming adherence-constrained, not just efficacy-constrained; that tends to favor products that reduce discontinuation and expand prescriber comfort in primary care. The flip side is that the bar is now much higher for any obesity entrant: if the oral path shows GI burden or weak durability, the stock likely loses the “multiple shots on goal” premium and reverts to a binary Phase III discount.

The near-term risk is timing mismatch: the equity can trade on setup excitement for several quarters, but the real fundamental inflection is still years away for the injectable program and at least months away for the oral initiation read-through. That leaves the name vulnerable to event-driven volatility around competitor data, capital markets risk for small-cap biotech, and any signal that obesity growth is normalizing faster than expected. In that scenario, the de-rating could be swift because the valuation is increasingly tied to future TAM share rather than current revenue.

Key Decisions for Investors

• Initiate a tactical long VKTX position ahead of oral Phase III start-up milestones; use a 3-6 month horizon and size for catalyst volatility rather than ultimate approval probability. Risk/reward favors upside on sequencing credibility, with downside if trial design or tolerability disappoints.
• Pair trade: long VKTX / short a basket of obesity incumbents with crowded ownership and higher expectations (e.g., LLY, NVO on a beta-neutral basis) for 1-2 quarters. Thesis: VKTX benefits from optionality and M&A convexity while incumbents are more exposed to any growth deceleration or access squeeze.
• Buy VKTX call spreads 6-12 months out to express upside into oral Phase III initiation without full downside exposure. Best structure is moderate-delta calls financed by selling further-out strikes; this captures rerating from execution updates while limiting capital at risk.
• If VKTX rallies sharply on trial-start news, trim 25-40% into strength and keep the remainder for binary Phase III readout optionality in 2027. The stock can reprice well before data, but the last leg of upside should be reserved for proof, not promise.
• For higher-risk accounts, consider a long VKTX / short small-cap biotech index hedge to isolate obesity-specific rerating while reducing financing and sentiment beta. This is attractive over the next 6-9 months if the market stays selective on pre-revenue biotech.